NCT04423536

Brief Summary

The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 7, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
9 months until next milestone

Study Start

First participant enrolled

March 9, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

May 9, 2022

Status Verified

May 1, 2022

Enrollment Period

4 years

First QC Date

June 7, 2020

Last Update Submit

May 6, 2022

Conditions

Natural Killer T-cell Lymphoma

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    5-years

Study Arms (2)

tested group

controlled group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

adults

You may qualify if:

  • biopsy proved Natural Killer T-cell Lymphoma
  • newly diagnosed patients

You may not qualify if:

  • patients with biopsy samples unavailable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,

Guangzhou, 51000, China

RECRUITING

Central Study Contacts

Qing qing Cai, MD

CONTACT

0086-20-87342823caiqq@sysucc.org.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief physician

Study Record Dates

First Submitted

June 7, 2020

First Posted

June 9, 2020

Study Start

March 9, 2021

Primary Completion

March 1, 2025

Study Completion

March 1, 2025

Last Updated

May 9, 2022

Record last verified: 2022-05

Locations

CN(1)